Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 2/20 | 0.94 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.94 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.94 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.94 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.94 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.94 |
| ▸ | PGR | P06401 | 2/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.94 |
| ▸ | SHBG | P04278 | 2/20 | 0.94 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.94 |
| ▸ | MAPT | P10636 | 2/20 | 0.94 |
| ▸ | LMNA | P02545 | 3/20 | 0.79 |
| ▸ | AR | P10275 | 1/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL3106980 | 1.00 | HIF1A (0.94) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL9622820 | 1.00 | HIF1A (0.94) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL8164979 | 0.97 | HIF1A (0.96) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL3999007 | 0.97 | HIF1A (0.96) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL24900238 | 0.97 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL143923 | 0.97 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL6932400 | 0.97 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL5699764 | 0.97 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL12737556 | 0.97 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 | |
| Hydrocortisone SCHEMBL10261067 | 0.97 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP3A4NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 19240 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2026-04-16 | — | — | US | claimed |
| US-12594260-B2 | Topical formulations for infections | Topical Rx, LLC (US) | 2026-04-07 | — | — | US | claimed |
| EP-3820479-B1 | METHODS TO REDUCE COMPLICATIONS OF INTRA-ARTICULAR STEROID | TAIWAN LIPOSOME CO LTD (TW) | 2026-03-11 | — | — | EP | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| EP-4673157-A2 | COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | Persephone Biosciences, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| US-20260000649-A1 | TOPICAL FORMULATIONS FOR INFECTIONS | TOPICAL RX LLC (US) | 2026-01-01 | — | — | US | claimed |
| WO-2025264805-A2 | SYNBIOTICS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | PERSEPHONE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| US-4137311-A | CORTICOSTEROIDS, METAL ADDUCTS OF BIS(2-PYRIDYL-1-OXIDE)-DISULFIDE; DERMATITIS, ANTIINFLAMMATORY | WILLIAM H. RORER, INC. (US) | 1979-01-30 | — | — | US | claimed |
| US-4130643-A | STEROID, SUCROSE ESTER, SULFOXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1978-12-19 | — | — | US | claimed |
| US-4115544-A | DRUG PARTICLES MIXED WITH RELEASE RATE-CONTROLLING HOMOPOLYMER | ALZA CORPORATION (US) | 1978-09-19 | — | — | US | claimed |
| US-4083974-A | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether | THE UPJOHN COMPANY (US) | 1978-04-11 | — | — | US | claimed |
| US-4014335-A | Ocular drug delivery device | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| US-4001388-A | POLYESTERS | ALZA CORPORATION (US) | 1977-01-04 | — | — | US | claimed |
| US-3981303-A | Bioerodible ocular device | ALZA CORPORATION (US) | 1976-09-21 | — | — | US | claimed |
| US-3962414-A | Structured bioerodible drug delivery device | ALZA CORPORATION (US) | 1976-06-08 | — | — | US | claimed |
| US-3962430-A | Sterilization of solid non-electrolyte medicinal agents employing sodium chloride | MERCK & CO., INC. (US) | 1976-06-08 | — | — | US | claimed |
| US-3960757-A | HYDROPHOBIC | TOYO JOZO CO., LTD. (JA) | 1976-06-01 | — | — | US | claimed |